Reason for request
Renewal of of the proprietary products BONVIVA 150 mg/1 month tablet (box of 1 and 3) and BONVIVA 3 mg/3 months (box of 1) on the list of medicines by National Health Insurance the renewal of of BONDRONAT solution for injection and re-assessment of the actual benefit of the proprietary product BONVIVA 3 mg/3 months solution for injection, box of 4, in accordance with article R. 163-21 of the Social Security Code.
Clinical Benefit
| Insufficient |
The actual benefit of these proprietary products in comparison with the treatments that are already available is not sufficient to justify reimbursement by National Health Insurance. |
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
ea2jdT4n0m5KLyNs
